Development of A Novel Highly Selective TLR8 Agonist for Cancer Immunotherapy
Y. Wang, H. Yang, H. Li…·D. Gao
This paper describes the development of DN052, a novel TLR8 agonist with high potency and selectivity, showing strong antitumor activity and favorable safety profile, leading to phase I clinical trials.